WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 525705
CAS#: 1030612-90-8 (free base);
Description: MK-8245 is a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window. MK-8245 was believed to inhibit the SCD enzyme solely in the liver and not in other tissues for the following reasons. When SCD inhibition has been measured by desaturation index in tissues of rodents treated with MK-8245, the desaturation index was significantly reduced in liver but not in other tissues such as skin, eye and adipose tissue.
MedKoo Cat#: 525705
CAS#: 1030612-90-8 (free base);
Chemical Formula: C15H14BrFN6O2
Molecular Weight: 409.21306
Elemental Analysis: C, 44.03; H, 3.45; Br, 19.53; F, 4.64; N, 20.54; O, 7.82
Related CAS #: 1415559-41-9 (TFA)
Synonym: MK-8245; MK8245; MK8245
IUPAC/Chemical Name: 4-(2-Bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)-3-isoxazolyl]piperidine
InChi Key: UDXUBDGJHLPKFJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H14BrFN6O2/c16-11-2-1-9(17)7-12(11)24-10-3-5-23(6-4-10)14-8-13(25-20-14)15-18-21-22-19-15/h1-2,7-8,10H,3-6H2,(H,18,19,21,22)
SMILES Code: FC1=CC=C(Br)C(OC2CCN(C3=NOC(C4=NNN=N4)=C3)CC2)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not soluble in water.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 409.21306 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Oballa RM, Belair L, Black WC, Bleasby K, Chan CC, Desroches C, Du X, Gordon R, Guay J, Guiral S, Hafey MJ, Hamelin E, Huang Z, Kennedy B, Lachance N, Landry F, Li CS, Mancini J, Normandin D, Pocai A, Powell DA, Ramtohul YK, Skorey K, SÃ¸rensen D, Sturkenboom W, Styhler A, Waddleton DM, Wang H, Wong S, Xu L, Zhang L. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011 Jul 28;54(14):5082-96. Epub 2011 Jun 28. PubMed PMID: 21661758.
MK-8245, a liver-targeted SCD inhibitor believed to inhibit the SCD enzyme solely in the liver and not in other tissues for the following reasons. When SCD inhibition has been measured by desaturation index in tissues of rodents treated with MK-8245, the desaturation index was significantly reduced in liver but not in other tissues such as skin, eye and adipose tissue.